Elan board rejects Royalty Pharma bid The board of Elan has unanimously rejected a formal bid from Royalty Pharma, saying the offer of $11.25 a share grossly undervalues the company. Business • 22 Apr 13
Elan board rejects Royalty Pharma bid The board of Elan has unanimously rejected a formal bid from Royalty Pharma, saying the offer of $11.25 a share grossly undervalues the company. Business • 22 Apr 13
Elan buyback reduces Royalty bid Elan said today that it bought back $1 billion of its shares at $11.25 a share. Business • 18 Apr 13
Elan buyback reduces Royalty bid Elan said today that it bought back $1 billion of its shares at $11.25 a share. Business • 18 Apr 13
Big US corporate deals drive 'Merger Monday' The more than $52 billion worth of deals announced yesterday made it the busiest "merger Monday" this year. Business • 16 Apr 13
Big US corporate deals drive 'Merger Monday' The more than $52 billion worth of deals announced yesterday made it the busiest "merger Monday" this year. Business • 16 Apr 13
Royalty Pharma offers new bid for Elan Royalty Pharma made a firm cash offer for Elan today of up to $12 per share, stepping up its efforts to take control of the Dublin based firm. Business • 15 Apr 13
Royalty Pharma offers new bid for Elan Royalty Pharma made a firm cash offer for Elan today of up to $12 per share, stepping up its efforts to take control of the Dublin based firm. Business • 15 Apr 13
Elan shareholders vote in favour of share buyback Elan shareholders have voted overwhelmingly in favour of a $1 billion share buyback scheme announced in February. Business • 12 Apr 13
Elan shareholders vote in favour of share buyback Elan shareholders have voted overwhelmingly in favour of a $1 billion share buyback scheme announced in February. Business • 12 Apr 13
Elan completes sale of Tysabri stake to Biogen Elan has closed the sale of its 50% stake in multiple sclerosis drug Tysabri. Business • 03 Apr 13
Elan completes sale of Tysabri stake to Biogen Elan has closed the sale of its 50% stake in multiple sclerosis drug Tysabri. Business • 03 Apr 13
Royalty Pharma ready to move quickly on Elan bid Royalty Pharma said today that it was standing by its offer to acquire Elan, which has rejected the approach. Business • 06 Mar 13
Royalty Pharma ready to move quickly on Elan bid Royalty Pharma said today that it was standing by its offer to acquire Elan, which has rejected the approach. Business • 06 Mar 13
Elan offers Tysabri dividend after Royalty bid Elan has said it will give shareholders 20% of the royalty rights for multiple sclerosis drug Tysabri. Business • 04 Mar 13
Elan offers Tysabri dividend after Royalty bid Elan has said it will give shareholders 20% of the royalty rights for multiple sclerosis drug Tysabri. Business • 04 Mar 13
Royalty Pharma offer highly opportunistic - Elan Elan shares are higher in Dublin trade today after the news that Royalty Pharma had made an indicative proposal to acquire the company. Business • 25 Feb 13
Royalty Pharma offer highly opportunistic - Elan Elan shares are higher in Dublin trade today after the news that Royalty Pharma had made an indicative proposal to acquire the company. Business • 25 Feb 13
Elan to use Tysabri proceeds to buy back shares Pharmaceutical company Elan said it will return $1 billion of the proceeds from selling its stake in the multiple sclerosis treatment Tysabri to shareholders. Business • 22 Feb 13
Elan to use Tysabri proceeds to buy back shares Pharmaceutical company Elan said it will return $1 billion of the proceeds from selling its stake in the multiple sclerosis treatment Tysabri to shareholders. Business • 22 Feb 13
Elan restructures Tysabri deal with Biogen Idec Elan has announced a restructuring of its MS drug Tysabri collaboration with Biogen Idec, which will see Biogen getting full ownership and control of multiple sclerosis drug Tysabri. Business • 06 Feb 13
Elan restructures Tysabri deal with Biogen Idec Elan has announced a restructuring of its MS drug Tysabri collaboration with Biogen Idec, which will see Biogen getting full ownership and control of multiple sclerosis drug Tysabri. Business • 06 Feb 13
Biogen profits slip on tax accounting error Biogen Idec's fourth-quarter net profit fell slightly due to a tax accounting error. Business • 28 Jan 13
Biogen profits slip on tax accounting error Biogen Idec's fourth-quarter net profit fell slightly due to a tax accounting error. Business • 28 Jan 13
Elan and Biogen eye MS drug sales boost Elan and Biogen Idec have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis. Business • 16 Jan 13
Elan and Biogen eye MS drug sales boost Elan and Biogen Idec have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis. Business • 16 Jan 13
Elan announces completion of demerger of Prothena Elan has announced completion of the separation of a substantial portion of its drug discovery business into a new independent, publicly traded company, Prothena. Business • 21 Dec 12
Elan announces completion of demerger of Prothena Elan has announced completion of the separation of a substantial portion of its drug discovery business into a new independent, publicly traded company, Prothena. Business • 21 Dec 12
Elan gives more details on Prothena move Elan has announced the expected timetable of the separation of a substantial portion of its drug discovery business into a new independent, publicly traded company called Prothena Corporation plc. Business • 17 Dec 12
Elan gives more details on Prothena move Elan has announced the expected timetable of the separation of a substantial portion of its drug discovery business into a new independent, publicly traded company called Prothena Corporation plc. Business • 17 Dec 12
Elan's Q3 revenues up 10%, but losses mount Elan has reported third quarter revenues of $306.6m for the three months to the end of September. Business • 24 Oct 12
Elan's Q3 revenues up 10%, but losses mount Elan has reported third quarter revenues of $306.6m for the three months to the end of September. Business • 24 Oct 12
Elan to spin off Neotope Biosciences unit The board of Elan has approved the spin-off of its discovery science and Neotope Biosciences from the company, in a move which makes Elan immediately profitable. Business • 13 Aug 12
Elan to spin off Neotope Biosciences unit The board of Elan has approved the spin-off of its discovery science and Neotope Biosciences from the company, in a move which makes Elan immediately profitable. Business • 13 Aug 12
Élan reports $60.3m loss in first half of 2012 Pharma group Élan has reported a net loss of $60.3m in the first half of 2012. Business • 25 Jul 12
Élan reports $60.3m loss in first half of 2012 Pharma group Élan has reported a net loss of $60.3m in the first half of 2012. Business • 25 Jul 12
Élan reports $22m first quarter operating profit Elan generated marginally less revenue than expected in the first quarter from sales of Tysabri, the multiple sclerosis drug that accounts for almost all of its earnings. Business • 26 Apr 12
Élan reports $22m first quarter operating profit Elan generated marginally less revenue than expected in the first quarter from sales of Tysabri, the multiple sclerosis drug that accounts for almost all of its earnings. Business • 26 Apr 12
